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Abstract: Duchenne and Becker muscular dystrophies (DMD/BMD) result in progressive weakness
of skeletal and cardiac muscles due to the deficiency of functional dystrophin. Respiratory failure is
a leading cause of mortality in DMD patients; however, improved management of the respiratory
symptoms have increased patients’ life expectancy, thereby also increasing the clinical relevance of
heart disease. In fact, the prevalence of cardiomyopathy, which significantly contributes to mortality
in DMD patients, increases with age and disease progression, so that over 95% of adult patients
has cardiomyopathy signs. We here review the current literature featuring the metabolic alterations
observed in the dystrophic heart of the mdx mouse, i.e., the best-studied animal model of the disease,
and discuss their pathophysiological role in the DMD heart. It is well assessed that dystrophin
deficiency is associated with pathological alterations of lipid metabolism, intracellular calcium levels,
neuronal nitric oxide (NO) synthase localization, and NO and reactive oxygen species production.
These metabolic stressors contribute to impair the function of the cardiac mitochondrial bulk, which
has a relevant pathophysiological role in the development of cardiomyopathy. In fact, mitochondrial
dysfunction becomes more severe as the dystrophic process progresses, thereby indicating it may be
both the cause and the consequence of the dystrophic process in the DMD heart.
Keywords: cardiomyopathy; Duchenne and Becker muscular dystrophy; metabolic alterations;
mitochondrial dysfunction
1. Introduction
Duchenne (DMD, OMIM #301200) and Becker muscular dystrophies (BMD, OMIM #300376)
are X-linked recessive degenerative disorders caused by mutations in the dystrophin gene (DMD,
HGNC:2928). Dystrophin (DMD, OMIM *300377) is a part of the dystrophin-associated glycoprotein
complex (DGC) that connects the cytoskeleton to the extracellular matrix [1]. Dystrophin binds to
actin filaments in the cytoskeleton and to DGC proteins in the plasma membrane and is essential
for the sarcolemmal structure and for protection from mechanical stress [2]. DGC also interacts with
proteins implicated in signaling pathways, such as neuronal nitric oxide synthase (nNOS or NOS1),
phosphoinositol triphosphate 2, calmodulin, and growth factor receptor-bound protein 2 [3]. Moreover,
DGC is involved in the extracellular signal-regulated kinases (ERK)/mitogen-activated protein kinase
(MAPK) signaling cascade [4] and is required for the clustering of ion channels and Ca2+ homeostasis [5].
The loss of functional dystrophin disrupts the DGC and NOS1, causing a decrease in sarcolemmal
structural integrity, as well as susceptibility to myofiber injury and dystrophy development (Figure 1).
The incidence of DMD and BMD is approximately 1 in 3500 and 1 in 20,000–30,000 live male
births, respectively [6]. DMD and, often, BMD are lethal conditions. Effective treatments are limited for
DMD patients, and research for genetic-based therapies is ongoing [7]. As a consequence, the analysis
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of the DMD gene is of utmost importance for the identification of the underlying molecular defect,
because it can confirm the clinical diagnosis, reveal patients’ genotype, address patients to the most
opportune therapeutic options, and allow the identification of carrier females and the application of
prenatal tests [8–10].J. Clin. Med. 2019, 8, x FOR PEER REVIEW 2 of 12 
 
Figure 1. Schematic representation of the dystrophin-associated glycoprotein complex in 
cardiomyocytes. Dystroglycans, sarcoglycans, and other key proteins involved are shown. nNOS: 
neuronal nitric oxide synthase, NO: nitric oxide, Cav1.2: cardiac voltage-dependent L-type calcium 
channel, NOX: NADPH oxidase, ROS: reactive oxygen species, PTP: permeability transition pore, 
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Patients affected by DMD lack the dystrophin protein and show progressive degeneration of 
skeletal muscles at 3–5 years of age and inability to walk at the age of about 10–12 years; their average 
life expectancy is of about 30 years of age. BMD patients have reduced content of the dystrophin 
protein and show a broad spectrum of clinical symptoms, a later disease onset, and a slower 
progression, with difficulties in ambulation that appear at a median age of 20 years [6]. The 
cardiomyocytes of DMD patients exhibit susceptibility to mechanical stress that contributes to heart 
fibrosis [11] and to the development of the often-lethal dilated cardiomyopathy (DCM) [12,13]. The 
cardiac pathology and the altered respiratory function caused by diaphragm damage leading to DCM 
are present in almost all DMD patients over 30 years of age and are the major causes of death at about 
40 years of age [14]. In patients with mild forms of BMD, symptoms are evident at the age of 30, and 
patients may be still ambulant at 60 years of age; however, they experience worse cardiomyopathy 
than DMD patients, and about 70% of them have left ventricular dysfunction [14]. DMD/BMD carrier 
females are usually asymptomatic, although some of them have clinical symptoms, due to X-
chromosome rearrangements involving the dystrophin locus or to unbalanced X inactivation [15]. 
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Patients affected by DMD lack the dystrophin protein and show progressive degeneration of
skeletal muscles at 3–5 years of age and inability to walk at the age of about 10–12 years; their average
life expectancy is of about 30 years of age. BMD patients have reduced content of the dystrophin protein
and show a broad spectrum of clinical symptoms, a lat r isease o set, and a slow r progression, with
difficulties in ambulation that appear at a median age of 20 years [6]. The cardiomyocytes of DMD
patients exhibit susceptibility to mechanical stress that contributes to heart fibrosis [11] and to the
development of the often-lethal dilated cardiomyopathy (DCM) [12,13]. The cardiac pathology and
the altered espir tory function caused by diaphragm da age leading to DCM re present in almost
all DMD patients over 30 years of age and are the major causes of death at about 40 years of age [14].
In patients with mild forms of BMD, symptoms are evident at the age of 30, and patients may be still
ambulant at 60 years of age; however, they experience worse cardio yopathy than MD patients,
and about 70% of them have left ven ricular dysfunction [14]. DMD/BMD carrier females are usually
asymptomatic, although some of them have clinical symptoms, due to X-chromosome rearrangements
involving the dystrophin locus or to unbalanced X inactivation [15].
Sarcole mal fragility due to the absence of dystrophin is associated with elevated cellular
Ca2+ that ause altered cell signaling, ecrosi f my fibrils, fibrosis, inflammation, and vascular
dysfunction in DMD patients. Therefore, dystrophinopathies are systemic diseases involving skeletal
and cardiac muscle myopathy, chronic inflammation, impaired signaling and metabolism. Mouse
models of DMD presenting disease progression similar to that in humans have been developed [16,17].
Recently, the hypothesis has been advanced that DMD/BMD are primarily metabolic diseases, and the
sarcolemmal damage is a downstream sequela [18].
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The aim of this paper is to review the main metabolic alterations occurring in the cardiomyocytes
of DMD patients.
2. Materials and Methods
This review was conducted according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) methodology [19]. The search covered the PubMed database (Figure 2).
The publications’ search period ranged from 2008 to 2019. The search term used was “Duchenne Becker”
combined with “metabolism”, “cardiomyopathy, metabolism”, or “cardiovascular cardiomyopathy
metabolism”. The selection of papers was based first on the titles and then on the abstracts. A word file
containing the selected papers was developed and available to all the co-authors. To be included in the
analysis, studies had to report alterations of cardiac metabolism in DMD/BMD patients or in animal
models. Full texts of selected articles were then analyzed, and only papers that reported and discussed
results supported by stringent experimental data carried out with appropriate methodologies were
included. Any issue encountered by an author when extracting the data was discussed collectively,
and a consensus was adopted to harmonize the extraction process. Manual searches were also made
using reference lists from the recovered articles. In total, 51 references found by manual search were
included; they concerned either articles reporting alterations of cardiac metabolism in DMD/BMD
patients or in animal models published before 2008 or articles dealing with general matter related to
the topic. Figure 2 describes the flowchart of this process.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 4 of 12 
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3. Results
3.1. Lipid Metabolism
Alterations in plasma and tissue lipids have been reported in DMD patients [20], and it has
been proposed that plasma lipids significantly contribute to pathology and that DMD patients could
benefit from lipid-lowering and vascular targeted therapies [21] (Table 1). Interestingly, it has been
reported that statins are pleiotropic drugs, and, in addition to their effect on lowering cholesterol,
they are involved in the regulation of processes implicated in DMD progression, such as autophagy
and NADPH oxidase 2-mediated oxidative stress (see also Section 3.3 Reactive Oxygen/Nitrogen Species
(ROS/RNS)) [22], and angiogenesis [23].
Table 1. Metabolic targets to treat cardiomyopathy in DMD/BMD patients.
Dysfunctional
Metabolism Molecular Alteration
Therapeutic
Target Available Drugs
Potential Therapeutic
Strategy
Lipids Increasedcholesterol-to-phospholipid ratio
Cholesterol
synthesis Statin
Mitochondria
Increased O2•− production
Impaired Ca2+ handling
Impaired oxidative
phosphorylation
Respiratory
complex I function Idebenone [24–26]
ROS Increased expression of NOX2Increased O2•− production
NOX2 Statin [22] NOX2 inhibition
RNS Lower NO levels Impaired NOS1activity
NO delivery NO
synthesis NO donors [27]
Accumulation of phosphatidylcholine, cholesterol, sphingomyelin, triglyceride, and increase in
monounsaturated fatty acid species have been detected in the muscles of DMD patients, while no
major modification of lipid metabolism was observed in BMD patients’ muscles, except for reduced
carnitine concentrations.
In particular, the cardiac involvement in DMD was investigated using animal models of DMD with
congestive cardiomyopathy [28,29]. In these animals, the total phospholipid content is significantly
reduced only in the heart and not in skeletal muscles; however, the phosphatidylcholine amount
and the cholesterol-to-phospholipid ratio are increased in both cardiac and skeletal muscles [30,31]
(Figure 3). Moreover, lower activity and expression of fatty acid synthase and stearoyl-CoA desaturase
in the liver, as well as decreased insulin levels have been detected in DMD mice compared to control
animals [32]. Insulin deficiency may in part cause impaired fatty acid metabolism. The increase in
cholesterol-to-phospholipid ratio could be ascribed to the release of phospholipids during muscle
degeneration, to increased activity of phospholipase A, and to increased cholesterol synthesis during
muscle regeneration [33].
3.2. Mitochondrial Impairment/Dysfunction
Cardiomyocytes are cells with elevated energy requirements that therefore are highly dependent
on mitochondrion activity. In these cells, mitochondria occupy approximately one-third of the cell
volume, actively synthesize ATP by oxidative phosphorylation, and are the major source of reactive
oxygen species (ROS) that can trigger oxidative stress and affect cell survival and death [34]. Moreover,
mitochondria are site for Ca2+ storage, because they release and withdraw Ca2+ to and from the
cell [35].
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Figure 3. Metabolic alterations in Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD)
cardiomyocytes. Dystrophin deficiency leads to sarcolemmal and cytoskeletal disruption and is associated
with mitochondrial dysfunction. As a consequence, metabolic alterations, which are mainly represented
by impaired Ca2+ homeostasis, oxidative stress, and bioenergetic impairment, occur both in the cytosol
(red box) and in the mitochondria (in green) and lastly cause cell death and apoptosis.
Dystrop in eficiency disrupts sarcolemmal stability and cytoskeletal organization, thereby
triggering a variety of cellular stress factors. Among these, increased oxidative stress, impaired
handling of cellular Ca2+, and strong decrease in nitric oxide (NO) signaling due to an impaired activity
of nNOS (or NOS1, OMIM *163731) have been reported in DMD patients and in a dystrophin-deficient
mouse model of DMD (mdx mouse) [36]. Moreover, in the initial compensatory phase that anticipates
clinical heart manifestations, cardiac remodeling shifts the energy production from mitochondrial
β-oxidation of long-chain fatty acids, which provides about three-quarters of the heart’s energy
requirement, to extra-mitochondrial oxidation of carbohydrates [37]. All these findings indicate that
mitochondrial metabolic alterations are present in DMD hearts before cardiomyopathy becomes overt.
Another prominent early factor in cardiomyopathy progression in DMD is the increased
susceptibility of mitochondria to open the permeability transition pore (PTP), a cyclosporine A- sensitive
high-conductance channel in the inner mitochondrial membrane (IMM) (Figure 1). As consequence of
PTP opening, which plays a key role in the pathogenesis of diseases due to necrotic cell death after
ischemic injuries or to muscle and brain degeneration [38], a nonspecific channel with an exclusion size
of 1.5 kDa is formed within the IMM. Physiological transient PTP opening allows a rapid Ca2+ release
and metabolite exchange between mitochondrial matrix and cytosol; in contrast, persistent opening
leads to pathological wasting of the IMM potential, resting of ATP synthesis, bioenergetic crisis, and
cell death—a main feature of mitochondrial disorders [38]. In the hearts of young mdx mice, before any
clinical evidence of cardiomyopathy, mitochondria that undergo PTP opening are significantly more
numerous than in normal hearts, thereby indicating that PTP opening has a key role in the pathogenesis
of dystrophic cardiomyopathy (Figure 3). Accumulation of Ca2+ in the mitochondrial matrix of
dystrophic muscle cells is one the main triggers of permeability transition [38]. In these cells, Ca2+
levels can increase as a consequence of the lack of dystrophin that favors sarcolemma disruption during
mechanical stress and, in the absence of sarcolemma disruption, through the voltage-independent
stretch-sensitive Ca2+ leak channels, the store-operated Ca2+ channels, and the ryanodine receptor [37].
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Also, the increase in ROS production may effectively induce PTP opening [38]. A major
source of ROS production in the muscle is the NADPH oxidase (NOX) enzyme. Expression and
activity of the NOX2 isoform are increased in cardiac myocytes from mdx mice (see also Section 3.3
Reactive Oxygen/Nitrogen Species (ROS/RNS)) [39]. The activation of NOX2 produces extracellularly the
superoxide anion (O2•−), which is converted to membrane-permeant H2O2 by extracellular superoxide
dismutase [39,40]. High levels of ROS lead to apoptosis or necrosis [34]. Oxidative stress that is present
in mitochondria from dystrophic hearts, increased PTP opening, and activation of caspase 9/3 reported
in young mdx hearts before the onset of cardiac impairment are all suggestive of mitochondria-derived
apoptosis [41] (Figure 3).
A very recent study demonstrates that, during altered oxidative phosphorylation, complex
I-sustained emission of mitochondrial H2O2 increases in the left ventricle of dystrophin-deficient
young mice, before any evidence of cardiac dysfunction [42]. Therefore, the identification of early
mitochondria-specific impairments may lead to the development of mitochondria-targeted therapies
able to recover respiratory chain activity and bioenergetic control, with the aim to delay the onset of
cardiomyopathy and the consequent progression to heart failure in DMD.
3.3. Reactive Oxygen/Nitrogen Species (ROS/RNS)
ROS-induced oxidative stress contributes to damage in Ca2+ handling and correlates with
cardiomyopathy progression and the severity of heart failure in DMD patients. Superoxide anion
(O2•−) is the main free radical formed in muscles.
The membrane-bound enzyme NOX is the major source of O2•− in the cardiovascular system
(Figure 1). Increased expression of the isoform NOX2 and O2•− production have been reported in the
hearts of mdx mice compared to those of wild-type controls [43]. NOX2 inhibition determines the
reduction of ROS levels toward levels similar to those of wild-type mice and restores the sarcoplasmic
reticulum (SR) Ca2+ content and the amplitude of evoked intracellular Ca2+ concentration transients
that are decreased in mdx mice [39,43]. The impairment of Ca2+ handling by oxidative stress occurs
essentially at the level of the RyR2 and Cav1.2 calcium channels, which are redox-sensitive (see also
Section 3.4 Calcium Handling). Consequently, increased ROS levels may in part explain the Ca2+ channel
abnormalities in dystrophic cardiomyocytes [36,44] (Figure 3 and Table 1).
The RNS NO is synthesized by NOS from L-arginine and oxygen and modulates a wide range
of physiological functions. NOS1 is a member of the DGC and is lost in a situation of dystrophin
deficiency [45]. Therefore, NOS1 deficiency could be the proximal cause of many of the poorly
understood features of the dystrophic phenotype. In particular, NO protects the cardiac muscle
through vascular relaxation and prevention of pathological hypertrophy [46]. However, there is
no evidence indicating that dystrophin and NOS1 co-localize at the membrane of wild-type mouse
cardiomyocytes [47]; on the contrary, NOS1 is localized at the intercalated discs, and its mislocalization
is associated with DMD cardiomyopathy [48]. This implies that the physical proximity of dystrophin
and NOS1 is not a key factor in NOS1 regulation in the heart and suggests an indirect, though efficient,
role for dystrophin in modulating NOS1 activity. Selective pharmacological inhibition of NOS1 in
wild-type cardiomyocytes lowers NO production, indicating that NOS1 is the main NOS isoform in
cardiomyocytes [47]. Cardiomyocytes from mdx mice produce significantly lower NO levels than
cardiomyocytes from wild-type mice (Figure 3) [47]. The use of transgenic NOS1 over-expression in
mdx mice prevents the development of many signs of cardiomyopathy [49]. Therapeutic strategies
have been developed to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide
availability in DMD [27] (Table 1).
3.4. Calcium Handling
Changes in excitation–contraction coupling and intracellular Ca2+ handling have been reported
in the hearts of mdx mice.
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The ryanodine receptor type 2 (RyR2, OMIM *180902) calcium channel and the voltage-dependent
L-type calcium channel (Cav1.2, OMIM *114205) are the two principal channels involved in
excitation–contraction coupling in the cardiac muscle. The activation of Cav1.2 by plasma membrane
depolarization allows Ca2+ to flow into the cell; Ca2+ binds to RyR2, a large homotetrameric Ca2+
release channel expressed in cardiomyocytes and located on the SR membrane (Figure 1), and induces
it to open and to release Ca2+ from the SR, thus triggering muscle contraction. This mechanism is
called calcium-induced calcium release (CICR). Several proteins, and also ATP, cations, such as Ca2+,
Mg2+, and pharmacological ligands regulate RyR2 activity.
Enhanced RyR2 activity has been associated with the pathogenesis of heart dysfunction in
DMD [50–52]. RyR2 protein levels are two- to three-fold greater in the hearts of dystrophin-deficient
mdx mice compared to those of wild-type mice [53]. Moreover, the increased protein kinase A
(PKA)-mediated phosphorylation of RyR2 at serine 2808 (S2808) afterβ-adrenergic activation contributes
to SR Ca2+ leak and to the development of heart failure [50]. In fact, inhibition of RyR2-S2808
phosphorylation in mdx mice largely prevents the development of age-related cardiomyopathy. Indeed,
progressive cardiac impairment in mdx mice seems to depend on the synergistic contribution of
both phosphorylation and oxidation of RyR2 [54]. Consistently, inhibition of RyR2 phosphorylation
suppresses SR Ca2+ leak in the mdx mouse heart in part by reducing RyR2 oxidation [54]. Therefore,
increased Ca2+ leak from the SR plays a crucial role in the development of cardiomyopathy in DMD.
Despite the lower NO levels produced in the cardiomyocytes of mdx mice compared to those of
wild-type mice [47], it has been reported that RyR2 is S-nitrosylated in mdx mice, resulting in a
functional remodeling of the RyR2 complex and in the dissociation of RyR2 from its stabilizing subunit
calstabin 2. These changes destabilize the RyR2 structure and increase SR Ca2+ leakage, leading to
intracellular Ca2+ increase and a diastolic SR Ca2+ leak (Figure 3) [52]. This remodeling is analogous to
the one observed in the skeletal muscle RyR1 channel complex following RyR1 S-nitrosylation [55].
The inhibition of calstabin 2 dissociation from the RyR2 complex suppresses the SR Ca2+ leak in
cardiomyocytes and prevents arrhythmias in vivo. Then, rescue of the RyR2-mediated diastolic SR
Ca2+ leak prevents fatal sudden arrhythmias in DMD hearts [52].
The voltage-dependent L-type calcium channel Cav1.2 co-localizes with dystrophin [56] and is
linked to F-actin networks by subsarcolemmal stabilizing proteins that finely regulate the channel
function [57]. Disruption of actin filaments significantly alters the Ca2+-L current [58]. Cardiomyocytes
from adult mdx mice show enhanced Ca2+ current densities and impaired Ca2+- and voltage-dependent
inactivation of the Cav1.2 channel compared to wild-type cardiomyocytes [59]. Ca2+ channel alterations
in dystrophic cardiomyocytes seem to be dependent on mice age and become more severe in the adult
age; in fact, a significantly reduced Ca2+ channel inactivation has been observed in the cardiomyocytes
of neonatal mdx mice [60]. Therefore, enhanced Ca2+ influx through Cav1.2 may contribute to
cardiomyopathy development (Figure 3) [60]. However, the functional properties of Cav1.2 are similar
in the cardiomyocytes from aged (>1 year of age) mdx and wild-type mice [61]. The loss of Cav1.2
dysregulation in the heart during aging can be ascribed to the significant decrease of dystrophin protein
in the senescent murine heart. In fact, the altered L-type Ca2+ currents in dystrophic hearts have
been explained by an impaired Cav1.2 regulation in the absence of dystrophin. Moreover, increased
basal phosphorylation of the Cav1.2 alpha1C subunit and enhanced PKA activity after β-adrenergic
activation in the hearts of mdx mice have been reported [62]. PKA-mediated phosphorylation of
Cav1.2 enhances the L-type Ca2+ currents and also affects the channel inactivation properties [63].
The enhanced PKA activity in dystrophic cardiomyocytes also explains the enhanced PKA-mediated
phosphorylation of RyR2 associated with dystrophic cardiomyopathy in mdx mice.
Another potential source of L-type Ca2+ currents alterations in dystrophic cardiomyocytes is the
redox modification of the Cav1.2 alpha1 subunit (cysteine 543 oxidation) during oxidative stress [64],
which results in an increase in the channel-mediated Ca2+ influx [63].
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Although it is well accepted that Cav1.2 is inhibited by NO via NOS1 activity in the heart, some
recent data do not confirm or even contradict this view [65]; therefore, the role of NO and NOS activity
in regulating Cav1,2 in the heart is still debated [65].
Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps Ca2+ from the cytosol into the lumen
of the SR, using the energy derived from ATP hydrolysis and is essential for the maintenance of
a low cytosolic Ca2+ concentration. SERCA2 protein expression in mdx mice is not significantly
different compared to that in wild-type hearts [53]. However, SERCA2 is reversibly inhibited by
phospholamban (PLN); phosphorylation of PLN at serine 16 and threonine 17 reverses this inhibition.
The phosphorylated PLN monomer content is lower in mdx compared to wild-type hearts. This
suggests that SERCA2 activity is affected in mdx mice, leading to increased decay constants of Ca2+
transients [53].
Intracellular calcium overload in DMD cardiomyocytes can also arise form an altered function
of other channels, such as Na+–H+ exchanger (NHE-1) and proton channels [66]. An increased Na+
influx through NHE-1 leads to an intracellular accumulation that, in turn, promotes calcium influx
through the Na+–Ca+2 exchanger.
4. Discussion
Metabolic impairment is evident not only in skeletal muscle but also in many tissues and cells from
DMD patients and animal models, including heart, liver, and brain. Therefore, it has been proposed
that DMD is characterized by a systemic metabolic impairment (Figure 3)—which is central to the
etiology of the disease and not secondary to its pathophysiology—and is primarily a mitochondrial
myopathy [18]. Disruption of sarcolemmal membrane and cytoskeletal organization are associated
with several cellular alterations, i.e., elevated cytosolic Ca2+, oxidative stress, and cell death, that may
cause mitochondrial dysfunctions and ultimately contribute to muscle fiber degeneration. Already
in 1992, Bonsett and Rudman [67] provided stringent evidence that adenylosuccinic acid (ASA)
treatment can induce positive effects in DMD patients because it restores the mitochondrial metabolic
impairment; indeed, ASA stimulates the Krebs and purine nucleotide cycles for ADP resynthesis,
thereby increasing mitochondrial ATP synthesis. ASA treatment actually induces broad improvements
in creatine retention and in the histology, energy levels, and strength of dystrophic muscles [67], which
are partially lost if the ASA therapy is suspended.
Very recently, it has been demonstrated that mitochondrial impairment anticipates the onset of
cardiomyopathy in a mouse model of DMD [42]. In particular, elevated mitochondrial H2O2 emission
and impaired oxidative phosphorylation have been detected in the left ventricle muscle of these mice at
an early age, when signs of cardiac dysfunction are absent, suggesting that mitochondrial dysfunction
plays a role in the etiology of the heart disease occurring at an older age [42].
Although changes induced by dystrophin deficiency, i.e., oxidative stress and impairment
of Ca2+ homeostasis, are involved in the development of cardiomyopathy in DMD patients,
mitochondrial dysfunction potentially contributes to cardiac dysfunction. Indeed, treatment with
idebenone—a quinone-based electron shuttle—improved cardiac and respiratory performance in DMD
patients [24–26] (Table 1), thereby providing further proof that the mitochondria are implicated in
DMD-associated heart dysfunction. Therefore, considering and treating DMD as a metabolic disease
could improve DMD therapies and the quality of life of patients.
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